ADC Therapeutics (ADCT) Gross Profit (2021 - 2026)

ADC Therapeutics (ADCT) posted quarterly Gross Profit of $17.4 million for Q1 2026, down 17.11% year-on-year from $21.0 million in Q1 2025, and up 14.18% on a QoQ basis from $15.2 million in Q3 2025.

ADC Therapeutics (ADCT) Gross Profit (2021 - 2026) Analysis & Trends

ADC Therapeutics (ADCT) has reported Gross Profit for 6 consecutive years, with $17.4 million the latest figure, recorded in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 ADC Therapeutics 189.60 Mn -41.41 Mn 17.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 17.38 Mn
Mar 31, 2026 17.38 Mn
Sep 30, 2025 15.23 Mn
Sep 30, 2025 15.23 Mn
Jun 30, 2025 18.00 Mn
Jun 30, 2025 18.00 Mn
Mar 31, 2025 20.97 Mn
Mar 31, 2025 20.97 Mn
Sep 30, 2024 17.61 Mn
Sep 30, 2024 17.61 Mn
Jun 30, 2024 16.19 Mn
Jun 30, 2024 16.19 Mn
Mar 31, 2024 15.54 Mn
Mar 31, 2024 15.54 Mn
Sep 30, 2023 14.13 Mn
Sep 30, 2023 14.13 Mn
Jun 30, 2023 17.96 Mn
Jun 30, 2023 17.96 Mn
Mar 31, 2023 18.40 Mn
Mar 31, 2023 18.40 Mn